Low Dose Weekly Decitabine/Venetoclax
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 85 patients (estimated)
- Sponsors
- Montefiore Medical Center (Moses Campus)
- Tags
- BCL-2 Inhibitor, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1856
- NCT Identifier
- NCT05184842
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.